Company news

Innate Pharma SA news in 2025

Innate Pharma SA's news releases, calls and decks from 2025, newest first.

View company

Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025

December 22, 2025

Innate Pharma Releases Its 2026 Financial Calendar

December 11, 2025

Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025

November 28, 2025

Innate Pharma to Present at Jefferies Global Healthcare Conference

November 17, 2025

Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results

November 13, 2025

Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL

November 10, 2025

Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates

November 5, 2025

Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025

October 14, 2025

Innate Pharma Reports First Half 2025 Business Update and Financial Results

September 17, 2025

Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event

September 15, 2025

Innate Pharma Announces Conference Call and Webcast for First Half 2025 Financial Results and Business Update

September 10, 2025

Number of Shares and Voting Rights of Innate Pharma as of September 1, 2025

September 2, 2025

Number of Shares and Voting Rights of Innate Pharma as of August 1, 2025

August 4, 2025

Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference

July 29, 2025

Number of Shares and Voting Rights of Innate Pharma as of July 3, 2025

July 4, 2025

Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences

June 17, 2025

Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress

June 13, 2025

Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences

May 27, 2025

Outcome of Innate Pharma’s 2025 Annual General Meeting

May 23, 2025

Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides

May 23, 2025

Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting

May 19, 2025

Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress

May 15, 2025

Innate Pharma Reports First Quarter 2025 Business Update and Financial Results

May 13, 2025

Number of Shares and Voting Rights of Innate Pharma as of May 5, 2025

May 12, 2025

Innate Pharma announces conference call and webcast for Q1 2025 business update

May 6, 2025

Innate Pharma Files Its 2024 Universal Registration Document (Document d’enregistrement universel) and 2024 Annual Report on Form 20-F

April 30, 2025

Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting

April 29, 2025

Calls in 2025

Decks in 2025